Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. - Wikidata - awgldk - TriplyDB

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

http://www.wikidata.org/entity/Q33464837

about

Interferon alpha for the adjuvant treatment of cutaneous melanoma Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?Active idiotypic vaccination versus control immunotherapy for follicular lymphoma Advanced malignant melanoma: immunologic and multimodal therapeutic strategies Immunologic functions as prognostic indicators in melanoma Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment Immune regulation of cancer Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.Cytokines in cancer immunotherapy.Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.Dendritic cell vaccination as a treatment modality for melanoma.Immunologic biomarkers as correlates of clinical response to cancer immunotherapy.Prognostic significance of autoimmunity during treatment of melanoma with interferon.Cutaneous melanoma: a model to study cancer metastasis.A new era in the treatment of melanoma: from biology to clinical practice.Adjuvant therapy for high-risk melanoma Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).Identification of Autoantibodies for α and γ-Enolase in Serum from a Patient with Melanoma.Adjuvant pegylated interferon α-2b therapy for melanoma Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort.Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).Melanoma & biomarkers of immunoresponsiveness

P2860

Q24235257-AE8A86A5-C5B0-4E64-B0F5-E8CF296707FC Q26796316-1DA1D270-8B18-4C4A-9F17-3AF4CDFB6421 Q33492805-BF89AB9C-9E0B-40B4-A99A-BED77AF69C73 Q33691505-EB847BE8-AE4E-4FFA-8B5A-045BEA407132 Q33717891-22E18223-A776-4CCC-9AEE-2922BA5D73CA Q33835011-208E08C0-B91B-45CB-A380-E26532805291 Q33851726-1AFE1665-AD06-4D7F-B9ED-4AD0057712FE Q34114136-4865536D-F4D1-45CB-B2C1-F20533388288 Q34586327-50A6615B-6B5E-4EBF-AC71-698352E5D3B7 Q34618599-E4DC0B93-2D33-41DB-8BE9-E4AFB4B6AAD3 Q35009135-F21993B4-D6B7-49B8-A652-4343A9CF29E2 Q35020518-892A86D7-A7A4-418B-8416-F4648DF092F4 Q36586109-0C62EC43-C097-438C-BDCF-943320E9AB97 Q36927476-16D9E039-F92D-4949-986B-A8D6767C0DD2 Q37148152-70D871C8-AA8F-4AFE-B4A8-5BD5FC11824D Q37628695-B6362CE9-8891-4C62-941B-38B61118D300 Q37628701-F3055B55-BFE1-4B40-9DD5-477D469CAE12 Q37827418-CDCB88A1-20FC-4E62-A183-1D05A8084273 Q37833559-75B6A3DB-4F4C-4BFC-A13E-2C307652EF12 Q37863622-728B783B-81B0-4AAB-8A20-E87F7700C5CD Q37956047-8368A1BC-1188-4575-A252-3FF994784A5D Q38555842-081F36B7-0556-4293-87FD-2EC3AFE0D0F6 Q39313889-A48A7B1B-091E-4205-904F-5AE861C749B4 Q39379568-1B4872BE-0FF4-473A-B9BD-8CDB509C9F13 Q41304720-8EFBBEB1-85E5-4B7A-9234-3833B86BC19C Q42323673-0C2557E7-9BF4-480E-A6E6-49F8BD06BA07 Q45001106-3EDAD244-BE14-486B-9461-D2D4339BCE01 Q50128100-0C3FA46B-3C6D-430B-AFA3-256A32A2E833 Q51035013-BC32C419-3930-42AA-A17C-27298BC3140B Q58234468-9176F581-DD75-4BFB-892A-AA8C7BDDDB68

P2860

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

http://www.wikidata.org/entity/Q33464837

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Autoimmune antibodies and recu ...... ated with adjuvant interferon.

@ast

Autoimmune antibodies and recu ...... ated with adjuvant interferon.

@en

type

label

Autoimmune antibodies and recu ...... ated with adjuvant interferon.

@ast

Autoimmune antibodies and recu ...... ated with adjuvant interferon.

@en

prefLabel

Autoimmune antibodies and recu ...... ated with adjuvant interferon.

@ast

Autoimmune antibodies and recu ...... ated with adjuvant interferon.

@en

P1433

Q33464837-50F2744F-CDF6-4B85-BE7B-1D593E06104D

P1476

Q33464837-B1586B66-C729-489F-99D9-DBEA33C4C520

P2093

Q33464837-1D1ECE8D-0FE5-4130-A1A2-007DC166DAF0

Q33464837-243D736A-BD73-482B-B0C1-569D7F48B069

Q33464837-3024FCF7-7E24-404B-8BDF-CA3434770E97

Q33464837-45C711A9-F304-4029-8C4E-E5D038FBA3CC

Q33464837-6392A486-8D3D-44A5-A58F-EA68EC91C579

Q33464837-6FDDC880-374A-49AF-B94C-438AFD046579

Q33464837-7C68582D-2A51-4B13-86B7-78BA80484E5C

Q33464837-88BA05AE-959E-4344-8C5F-5711F1FD41B4

Q33464837-91AF41A5-8440-474D-8A49-123F1A69D83D

Q33464837-97FAEEB4-37A8-4FA0-8140-5BED04E6A464

P2860

Q33464837-064A4C48-0063-4D2C-8318-68ABFEEF930D

Q33464837-09AA20DB-A616-4724-AC5D-34EE9BE2A42C

Q33464837-1F7CD2CE-0F31-465A-A0A4-6ED4F43A33A1

Q33464837-3ACC8E08-3325-4A6B-A985-871E32CBD52E

Q33464837-3B964682-9173-4B8A-A7D1-F80D219B4FEE

Q33464837-4E4044BE-695E-47A4-B5CE-31B0B4430C39

Q33464837-530BD797-DD5A-4DCF-A5A1-FF4415751378

Q33464837-5F8CE6C2-C510-4B7D-8922-342F537F7B94

Q33464837-BB5ECF85-29E9-4DF9-836F-1081720C7495

Q33464837-CE061253-28A4-4840-B9BF-B48DD80268F9

P304

Q33464837-2BA28B4C-8B85-4CE8-9F0D-3D37A6B1A18E

P31

Q33464837-8C90CC2C-11A0-404D-9BEE-D7DE7D5025C3

P356

Q33464837-BEF0F453-DFE4-40AB-A85B-56C696505F15

P407

Q33464837-A862451F-63AC-4E63-865B-6BE8409ACF5C

P433

Q33464837-CAE0DAC9-4560-4EE4-A329-0ACF54787902

P478

Q33464837-BFF8F058-608D-4E74-87A7-CA69536DE0DB

P50

Q33464837-31CE28CB-EE15-437B-BEC2-4EA1F1F1A26A

Q33464837-530BB3F0-F9D8-45AD-AEEE-73820F8E1BA3

P577

Q33464837-40EBA5BF-1ADE-4546-8067-E9E2517F9F41

P698

Q33464837-0B9205C7-3617-4257-87D2-5D2A4581D961

P921

Q33464837-939C1FF6-3D6F-410B-B759-F3CD715F32D0

P356

P1433

Journal of the National Cancer Institute

P1476

Autoimmune antibodies and recu ...... ated with adjuvant interferon.

@en

P2093

Alain Spatz

http://www.w3.org/2001/XMLSchema#string

Alexander M M Eggermont

http://www.w3.org/2001/XMLSchema#string

Cornelis J A Punt

http://www.w3.org/2001/XMLSchema#string

EORTC Melanoma Group and the Nordic Melanoma Group

http://www.w3.org/2001/XMLSchema#string

François Salès

http://www.w3.org/2001/XMLSchema#string

Johan Hansson

http://www.w3.org/2001/XMLSchema#string

Marna G Bouwhuis

http://www.w3.org/2001/XMLSchema#string

Micaela Hernberg

http://www.w3.org/2001/XMLSchema#string

Poulam Patel

http://www.w3.org/2001/XMLSchema#string

Sandra Collette

http://www.w3.org/2001/XMLSchema#string

P2860

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Range of antinuclear antibodies in "healthy" individuals.

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes.

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings.

Analysis of survival by tumor response.

P304

869-877

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJP132

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Eggermont

P577

2009-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19509353

http://www.w3.org/2001/XMLSchema#string

P921